Glaukos Corp (NYSE:GKOS) Expected to Post Earnings of -$0.11 Per Share
Brokerages expect Glaukos Corp (NYSE:GKOS) to announce earnings per share of ($0.11) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Glaukos’ earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.12). Glaukos reported earnings of $0.04 per share in the same quarter last year, which would suggest a negative year over year growth rate of 375%. The firm is scheduled to report its next quarterly earnings results on Wednesday, February 26th.
On average, analysts expect that Glaukos will report full year earnings of ($0.62) per share for the current year, with EPS estimates ranging from ($0.70) to ($0.47). For the next financial year, analysts anticipate that the business will post earnings of ($0.12) per share, with EPS estimates ranging from ($0.39) to $0.08. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that cover Glaukos.
Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, November 6th. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. Glaukos had a negative net margin of 8.60% and a negative return on equity of 4.01%. The firm had revenue of $58.51 million during the quarter, compared to analysts’ expectations of $56.96 million. During the same period last year, the business earned ($0.17) earnings per share. Glaukos’s revenue was up 33.2% compared to the same quarter last year.
In related news, CFO Joseph E. Gilliam sold 2,500 shares of Glaukos stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $73.25, for a total value of $183,125.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 10,881 shares of company stock valued at $716,702 in the last ninety days. 8.70% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marshall Wace North America L.P. bought a new position in Glaukos in the 1st quarter valued at $55,000. Amundi Pioneer Asset Management Inc. lifted its position in shares of Glaukos by 136.7% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 178,502 shares of the medical instruments supplier’s stock worth $13,989,000 after purchasing an additional 103,102 shares during the period. NEXT Financial Group Inc lifted its position in shares of Glaukos by 73.7% in the 2nd quarter. NEXT Financial Group Inc now owns 1,129 shares of the medical instruments supplier’s stock worth $85,000 after purchasing an additional 479 shares during the period. First Quadrant L P CA purchased a new position in shares of Glaukos during the second quarter valued at about $86,000. Finally, Strs Ohio increased its position in shares of Glaukos by 1,085.7% during the second quarter. Strs Ohio now owns 16,600 shares of the medical instruments supplier’s stock valued at $1,251,000 after buying an additional 15,200 shares during the period.
NYSE:GKOS remained flat at $$61.10 on Wednesday. 15,252 shares of the company’s stock traded hands, compared to its average volume of 520,947. The company has a debt-to-equity ratio of 0.42, a quick ratio of 5.94 and a current ratio of 6.32. The firm has a market capitalization of $2.23 billion, a PE ratio of -165.14 and a beta of 1.66. The stock has a fifty day moving average price of $63.44 and a two-hundred day moving average price of $67.89. Glaukos has a 12 month low of $50.60 and a 12 month high of $84.65.
Glaukos Company Profile
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.
Recommended Story: Capital Gains
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.